sST2 and Galectin-3 genotyping in patients with persistent atrial fibrillation

Saez-Maleta, Ruth; Merino-Merino, Ana; Gundín‐Menéndez, Simón; Salgado-Aranda, Ricardo; AlKassam-Martinez, Daniel; Pascual-Tejerina, Virginia; Martín‐González, Javier; García-Fernández, Javier; Rivera, Jaime A.

doi:10.1007/s11033-021-06150-1

Cited by 5 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Those patients carrying the mutated allele of the ST2 polymorphism rs1558648 had lower ST2 values measured at baseline but not at the 6-month follow-up. As a conclusion, the identification of genetic predisposition to present higher levels of harmful biomarkers might facilitate the individualization of the diagnosis or the therapeutic strategy [14].…”

Section: St2 and Galectin-3: Basic Conceptsmentioning

confidence: 99%

The Role of Galectin-3 and ST2 in Cardiology: A Short Review

Merino-Merino¹,

González-Bernal

Fernandez-Zoppino

et al. 2021

Biomolecules

Self Cite

View full text Add to dashboard Cite

Galectin-3 is a lectin that binds beta-galactosides. It is involved in cardiac remodeling and fibrosis through the activation of macrophages and fibroblasts. ST2 is secreted by myocardial cells due to cardiac overload. These two biomarkers have been traditionally studied in the field of heart failure to guide medical therapy and detect the progression of the disease. Nevertheless, there are novel evidences that connect galectin-3 and ST2 with coronary heart disease and, specifically, with atrial fibrillation. The aim of this article is to concisely review the diagnostic and prognostic role of galectin-3 and ST2 in different cardiac diseases.

show abstract

Section: St2 and Galectin-3: Basic Conceptsmentioning

confidence: 99%

The Role of Galectin-3 and ST2 in Cardiology: A Short Review

Merino-Merino¹,

González-Bernal

Fernandez-Zoppino

et al. 2021

Biomolecules

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although the authors of the study established a correlation between the Gal-3 levels and oxidative stress and inflammation in AF patients, only circulating myeloperoxidase, but not Gal-3, was associated with the maintenance of sinus rhythm in a multivariate model, possibly due to the small number of patients and relatively early stage of AF [102]. Whether these changes may be explained in connection with single nuclear polymorphisms of the Gal-3 gene has not been fully elucidated [103]. Thus, the predictive ability of Gal-3 for sinus rhythm restoration following successful electrical cardioversion requires thorough investigations in face-to-face comparison with other biomarkers before implementation in clinical practice.…”

Section: Galectin-3mentioning

confidence: 93%

Biomarkers of Atrial Fibrillation Recurrence in Patients with Paroxysmal or Persistent Atrial Fibrillation Following External Direct Current Electrical Cardioversion

et al. 2023

View full text Add to dashboard Cite

Atrial fibrillation (AF) is associated with atrial remodeling, cardiac dysfunction, and poor clinical outcomes. External direct current electrical cardioversion is a well-developed urgent treatment strategy for patients presenting with recent-onset AF. However, there is a lack of accurate predictive serum biomarkers to identify the risks of AF relapse after electrical cardioversion. We reviewed the currently available data and interpreted the findings of several studies revealing biomarkers for crucial elements in the pathogenesis of AF and affecting cardiac remodeling, fibrosis, inflammation, endothelial dysfunction, oxidative stress, adipose tissue dysfunction, myopathy, and mitochondrial dysfunction. Although there is ample strong evidence that elevated levels of numerous biomarkers (such as natriuretic peptides, C-reactive protein, galectin-3, soluble suppressor tumorigenicity-2, fibroblast growth factor-23, turn-over collagen biomarkers, growth differential factor-15) are associated with AF occurrence, the data obtained in clinical studies seem to be controversial in terms of their predictive ability for post-cardioversion outcomes. Novel circulating biomarkers are needed to elucidate the modality of this approach compared with conventional predictive tools. Conclusions: Biomarker-based strategies for predicting events after AF treatment require extensive investigation in the future, especially in the presence of different gender and variable comorbidity profiles. Perhaps, a multiple biomarker approach exerts more utilization for patients with different forms of AF than single biomarker use.

show abstract

“…Lastly, a recent study analyzed the relationship between levels of Gal-3 genotyping and persistent AF. They found that between the three polymorphisms in patients (Rs2274273, Rs1558648, and rs13019803), Rs2274273 was significantly related to the levels of Gal-3 [ 67 ]. This field might improve our understanding of Gal-3 and its role in developing AF and needs further research and exploration.…”

Section: Gal-3 and Afmentioning

confidence: 99%

Insights into the Role of Galectin-3 as a Diagnostic and Prognostic Biomarker of Atrial Fibrillation

Mohtasham Kia,

Cannavo,

Bahiraie

et al. 2023

Disease Markers

View full text Add to dashboard Cite

Atrial fibrillation (AF) is an irregular atrial activity and the most prevalent type of arrhythmia. Although AF is easily diagnosed with an electrocardiogram, there is a keen interest in identifying an easy-to-dose biomarker that can predict the prognosis of AF and its recurrence. Galectin-3 (Gal-3) is a beta-galactoside binding protein from the lectin family with pro-fibrotic and -inflammatory effects and a pivotal role in a variety of biological processes, cell proliferation, and differentiation; therefore, it is implicated in the pathogenesis of many cardiovascular (e.g., heart failure (HF)) and noncardiovascular diseases. However, its specificity and sensitivity as a potential marker in AF patients remain debated and controversial. This article comprehensively reviewed the evidence regarding the interplay between Gal-3 and patients with AF. Clinical implications of measuring Gal-3 in AF patients for diagnosis and prognosis are mentioned. Moreover, the role of Gal-3 as a potential biomarker for the management of AF recurrence is investigated. The association of Gal-3 and AF in special populations (coronary artery disease, HF, metabolic syndrome, chronic kidney disease, and diabetes mellitus) has been explored in this review. Overall, although further studies are needed to enlighten the role of Gal-3 in the diagnosis and treatment of AF, our study demonstrated the high potential of this molecule to be used and focused on by researchers and clinicians.

show abstract

sST2 and Galectin-3 genotyping in patients with persistent atrial fibrillation

Cited by 5 publications

References 21 publications

The Role of Galectin-3 and ST2 in Cardiology: A Short Review

The Role of Galectin-3 and ST2 in Cardiology: A Short Review

Biomarkers of Atrial Fibrillation Recurrence in Patients with Paroxysmal or Persistent Atrial Fibrillation Following External Direct Current Electrical Cardioversion

Insights into the Role of Galectin-3 as a Diagnostic and Prognostic Biomarker of Atrial Fibrillation

Contact Info

Product

Resources

About